<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059187</url>
  </required_header>
  <id_info>
    <org_study_id>1293-006</org_study_id>
    <secondary_id>2012-003478-19</secondary_id>
    <nct_id>NCT02059187</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)</brief_title>
  <official_title>A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 24-week study is a safety and efficacy comparison of MK-1293 and Lantus™ in participants
      with type 2 diabetes mellitus (T2DM). The primary hypothesis is that after 24 weeks, the mean
      change in hemoglobin A1c (A1C) from baseline is non-inferior (with margin of 0.4%) in
      participants treated with MK-1293 compared with that in participants treated with Lantus™.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Participant Hemoglobin A1C Level at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>A1C is measured as a percent. A1C is the key glycemic parameter which correlates with reduction of risk of diabetic complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Percentage of participants is a cumulative percentage of participants with any confirmed AIA (including baseline) up to Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant Body Weight at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change from baseline in participant body weight at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing an Adverse Event (AE) of Hypoglycemia Up to Week 24</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Symptomatic events assessed as likely to be hypoglycemia were to be reported by investigators as adverse events of hypoglycemia; a concurrent glucose measurement was not required. Asymptomatic events with confirmed glucose levels &lt;/= 70mg/dL (&lt;/= 3.9mmol/L) could also be reported as adverse events at the discretion of the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing an AE Over the 24-week Treatment Period</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Basal Insulin Dose (Units) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The daily basal insulin dose (measured in units) for any given visit is defined as the average dose from the three most recent days preceding the visit date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Basal Insulin Dose Per Body Weight (Units/kg) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Basal insulin dose per body weight was calculated as total insulin dose (units) per day divided by body weight in kilograms (kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant Fasting Plasma Glucose (FPG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Participants fasted (no food or drink except water and non-antihyperglycemic non-study medications as prescribed) for at least 8 hours prior to all study visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant 7-Point Average of Self-Monitored Blood Glucose (SMBG) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>7-Point Average of SMBG was defined as the mean of blood glucose measurements taken at the following 7 times: before morning meal, after morning meal, before midday meal, after midday meal, before evening meal, after evening meal or at bedtime, and between 2 AM and 4 AM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hemoglobin A1C &lt;7% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with A1C &lt;7.0% (53 mmol/mol) at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hemoglobin A1C &lt;6.5% at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with A1C &lt;6.5% (48 mmol/mol) at Week 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">531</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK-1293</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-1293 administered subcutaneously once daily in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lantus™ administered subcutaneously once daily in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-1293</intervention_name>
    <description>MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.</description>
    <arm_group_label>MK-1293</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus™</intervention_name>
    <description>Lantus™ (insulin glargine [rDNA origin]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.</description>
    <arm_group_label>Lantus™</arm_group_label>
    <other_name>Insulin glargine [rDNA origin]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prandial insulin</intervention_name>
    <description>Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.</description>
    <arm_group_label>MK-1293</arm_group_label>
    <arm_group_label>Lantus™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 2 Diabetes Mellitus (T2DM) as defined by the American Diabetes
             Association (ADA) or the European Association for the Study of Diabetes (EASD)

          -  hemoglobin A1C of ≤11.0% and requires insulin for glycemic control

          -  Body mass index (BMI) &lt;45 kg/m^2

        Exclusion Criteria:

          -  History of type 1 diabetes mellitus or a history of ketoacidosis, or has type 1
             diabetes confirmed with a C-peptide &lt;0.7 ng/mL (0.23 nmol/L)

          -  One or more severe hypoglycemic episodes associated with hypoglycemic seizures, comas
             or unconsciousness within the past 6 months

          -  History of intolerance or hypersensitivity to Lantus™ or contraindication to Lantus™
             or one of its excipients based on the label of the country of the investigational site

          -  On a weight loss program within the last 8 weeks

          -  Received injectable incretin-based therapy (e.g., Victoza™, Byetta™) within the prior
             8 weeks

          -  Bariatric surgery within 12 months prior to signing the informed consent

          -  Likely to require treatment for ≥2 consecutive weeks or repeated courses of
             corticosteroids

          -  Undergone a surgical procedure within 4 weeks prior to signing informed consent or has
             planned major surgery during the study

          -  New or worsening signs or symptoms of coronary heart disease or congestive heart
             failure within the last 3 months

          -  Presence of any of the following during the last 3 months: acute coronary syndrome,
             coronary artery intervention, and/or stroke or transient ischemic neurological
             disorder

          -  Severe peripheral vascular disease

          -  Systolic blood pressure ≥ 160 mm Hg or a diastolic ≥95 mm Hg and blood pressure is not
             considered likely to be under these limits with an adjustment in antihypertensive
             medication

          -  Chronic myopathy or a progressive neurological or neuromuscular disorder

          -  Active nephropathy

          -  History of active liver disease (other than non-alcoholic hepatic steatosis),
             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic
             gallbladder disease

          -  Human immunodeficiency virus (HIV)

          -  Clinically important hematological disorder (such as aplastic anemia,
             myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

          -  History of malignancy ≤5 years prior to signing informed consent, except for
             adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer

          -  History of melanoma, leukemia, lymphoma, or renal cell carcinoma

          -  Hyperthyroidism

          -  On a stable dose of thyroid hormone replacement therapy for &lt;6 weeks

          -  Uses recreational or illicit drugs or has had a recent history (within the last year)
             of drug or alcohol abuse or dependence

          -  Pregnant or breast-feeding, or is expecting to conceive or donate eggs during the
             study, including 14 days following the last dose of study drug

          -  Donated blood products or has had phlebotomy of &gt;300 mL within 8 weeks of signing
             informed consent, or intends to donate blood products within the projected duration of
             the study

          -  Poor mental function or any other reason to expect that the participant may have
             difficulty in complying with the requirements of the study

          -  Clinically significant ECG abnormality which exposes the participant to risk by
             enrolling in the study

          -  Positive urine pregnancy test

          -  Participant is a night shift worker which causes difficulty complying with the
             overnight fast requirement and has potential for confounding the 7-point SMBG analysis

          -  Participant, as assessed by the investigator, is not appropriate for or does not agree
             to target a fasting glucose of 70-100 mg/dL [3.9 -5.6 mmol/L]

          -  Has used a formulation of glargine insulin other than Lantus™
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Colombia</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>January 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 8, 2017</results_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-1293</title>
          <description>MK-1293 administered subcutaneously once daily.</description>
        </group>
        <group group_id="P2">
          <title>Lantus™</title>
          <description>Lantus™ administered subcutaneously once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
                <participants group_id="P2" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>MK-1293</title>
          <description>MK-1293 administered subcutaneously once daily.</description>
        </group>
        <group group_id="B2">
          <title>Lantus™</title>
          <description>Lantus™ administered subcutaneously once daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="265"/>
            <count group_id="B2" value="266"/>
            <count group_id="B3" value="531"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="10.0" lower_limit="20" upper_limit="80"/>
                    <measurement group_id="B2" value="57.1" spread="9.8" lower_limit="31" upper_limit="79"/>
                    <measurement group_id="B3" value="57.0" spread="9.9" lower_limit="20" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Participant Hemoglobin A1C Level at Week 24</title>
        <description>A1C is measured as a percent. A1C is the key glycemic parameter which correlates with reduction of risk of diabetic complications.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant Hemoglobin A1C Level at Week 24</title>
          <description>A1C is measured as a percent. A1C is the key glycemic parameter which correlates with reduction of risk of diabetic complications.</description>
          <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
          <units>Percent A1C</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" lower_limit="-1.41" upper_limit="-1.15"/>
                    <measurement group_id="O2" value="-1.30" lower_limit="-1.43" upper_limit="-1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>MK-1293 was to be considered non-inferior to Lantus in type 2 diabetes mellitus (T2DM) if the upper bound of the two-sided 95% confidence interval (CI) for the between-treatment difference (MK-1293 minus Lantus) in least-squares (LS) means was below 0.4% based on a cLDA model.</non_inferiority_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24</title>
        <description>Percentage of participants is a cumulative percentage of participants with any confirmed AIA (including baseline) up to Week 24.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Confirmed Anti-Insulin Antibodies (AIA) up to Week 24</title>
          <description>Percentage of participants is a cumulative percentage of participants with any confirmed AIA (including baseline) up to Week 24.</description>
          <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="262"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7"/>
                    <measurement group_id="O2" value="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>13.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant Body Weight at Week 24</title>
        <description>Change from baseline in participant body weight at Week 24.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant Body Weight at Week 24</title>
          <description>Change from baseline in participant body weight at Week 24.</description>
          <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.6"/>
                    <measurement group_id="O2" value="1.4" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing an Adverse Event (AE) of Hypoglycemia Up to Week 24</title>
        <description>Symptomatic events assessed as likely to be hypoglycemia were to be reported by investigators as adverse events of hypoglycemia; a concurrent glucose measurement was not required. Asymptomatic events with confirmed glucose levels &lt;/= 70mg/dL (&lt;/= 3.9mmol/L) could also be reported as adverse events at the discretion of the investigator.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an Adverse Event (AE) of Hypoglycemia Up to Week 24</title>
          <description>Symptomatic events assessed as likely to be hypoglycemia were to be reported by investigators as adverse events of hypoglycemia; a concurrent glucose measurement was not required. Asymptomatic events with confirmed glucose levels &lt;/= 70mg/dL (&lt;/= 3.9mmol/L) could also be reported as adverse events at the discretion of the investigator.</description>
          <population>All randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0"/>
                    <measurement group_id="O2" value="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing an AE Over the 24-week Treatment Period</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an AE.</description>
        <time_frame>Up to 24 weeks</time_frame>
        <population>All randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing an AE Over the 24-week Treatment Period</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the investigational product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the investigational product, is also an AE.</description>
          <population>All randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in percent</param_type>
            <param_value>6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Basal Insulin Dose (Units) at Week 24</title>
        <description>The daily basal insulin dose (measured in units) for any given visit is defined as the average dose from the three most recent days preceding the visit date.</description>
        <time_frame>Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Basal Insulin Dose (Units) at Week 24</title>
          <description>The daily basal insulin dose (measured in units) for any given visit is defined as the average dose from the three most recent days preceding the visit date.</description>
          <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
          <units>Units</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" lower_limit="44.9" upper_limit="51.5"/>
                    <measurement group_id="O2" value="46.9" lower_limit="43.5" upper_limit="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS means</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Basal Insulin Dose Per Body Weight (Units/kg) at Week 24</title>
        <description>Basal insulin dose per body weight was calculated as total insulin dose (units) per day divided by body weight in kilograms (kg).</description>
        <time_frame>Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Basal Insulin Dose Per Body Weight (Units/kg) at Week 24</title>
          <description>Basal insulin dose per body weight was calculated as total insulin dose (units) per day divided by body weight in kilograms (kg).</description>
          <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
          <units>Units/kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="262"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" lower_limit="0.49" upper_limit="0.56"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.48" upper_limit="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Dofference in LS means</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant Fasting Plasma Glucose (FPG) at Week 24</title>
        <description>Participants fasted (no food or drink except water and non-antihyperglycemic non-study medications as prescribed) for at least 8 hours prior to all study visits.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant Fasting Plasma Glucose (FPG) at Week 24</title>
          <description>Participants fasted (no food or drink except water and non-antihyperglycemic non-study medications as prescribed) for at least 8 hours prior to all study visits.</description>
          <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="263"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.0" lower_limit="-41.3" upper_limit="-28.6"/>
                    <measurement group_id="O2" value="-38.4" lower_limit="-44.8" upper_limit="-32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS means</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>10.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Participant 7-Point Average of Self-Monitored Blood Glucose (SMBG) at Week 24</title>
        <description>7-Point Average of SMBG was defined as the mean of blood glucose measurements taken at the following 7 times: before morning meal, after morning meal, before midday meal, after midday meal, before evening meal, after evening meal or at bedtime, and between 2 AM and 4 AM.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Participant 7-Point Average of Self-Monitored Blood Glucose (SMBG) at Week 24</title>
          <description>7-Point Average of SMBG was defined as the mean of blood glucose measurements taken at the following 7 times: before morning meal, after morning meal, before midday meal, after midday meal, before evening meal, after evening meal or at bedtime, and between 2 AM and 4 AM.</description>
          <population>The analysis population included all randomized, treated participants who had at least one observation for the analysis endpoint.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.7" lower_limit="-37.6" upper_limit="-23.8"/>
                    <measurement group_id="O2" value="-27.3" lower_limit="-34.0" upper_limit="-20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in LS Means</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hemoglobin A1C &lt;7% at Week 24</title>
        <description>Percentage of participants with A1C &lt;7.0% (53 mmol/mol) at Week 24.</description>
        <time_frame>Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants with a Week 24 A1C measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hemoglobin A1C &lt;7% at Week 24</title>
          <description>Percentage of participants with A1C &lt;7.0% (53 mmol/mol) at Week 24.</description>
          <population>The analysis population included all randomized, treated participants with a Week 24 A1C measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5"/>
                    <measurement group_id="O2" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted difference in percent</param_type>
            <param_value>2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>11.6</ci_upper_limit>
            <estimate_desc>Calculated via Miettinen and Nurminen method, stratified by prior insulin status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Hemoglobin A1C &lt;6.5% at Week 24</title>
        <description>Percentage of participants with A1C &lt;6.5% (48 mmol/mol) at Week 24.</description>
        <time_frame>Week 24</time_frame>
        <population>The analysis population included all randomized, treated participants with a Week 24 A1C measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-1293</title>
            <description>MK-1293 administered subcutaneously once daily.</description>
          </group>
          <group group_id="O2">
            <title>Lantus™</title>
            <description>Lantus™ administered subcutaneously once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Hemoglobin A1C &lt;6.5% at Week 24</title>
          <description>Percentage of participants with A1C &lt;6.5% (48 mmol/mol) at Week 24.</description>
          <population>The analysis population included all randomized, treated participants with a Week 24 A1C measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted difference in percent</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.3</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
            <estimate_desc>Calculated via Miettinen and Nurminen method, stratified by prior insulin status.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 26 weeks (including 2-week follow-up for serious adverse events)</time_frame>
      <desc>All randomized participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-1293</title>
          <description>MK-1293 administered subcutaneously once daily.</description>
        </group>
        <group group_id="E2">
          <title>Lantus™</title>
          <description>Lantus™ administered subcutaneously once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Mitral valve disease mixed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral small vessel ischaemic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="263"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="263"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="263"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="263"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1352" subjects_affected="142" subjects_at_risk="263"/>
                <counts group_id="E2" events="1141" subjects_affected="142" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

